Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock financial statements, including revenue, expenses, profit, and loss

The total revenue of FBIOP for the last quarter is 19.95 M USD, and it's 42.60% lower compared to the previous quarter. The net income of Q4 23 is -9.28 M USD.